These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

364 related items for PubMed ID: 15787825

  • 21. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma.
    Perceau G, Diris N, Estines O, Derancourt C, Lévy S, Bernard P.
    Br J Dermatol; 2006 Nov; 155(5):1053-6. PubMed ID: 17034541
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
    Law CL, Cerveny CG, Gordon KA, Klussman K, Mixan BJ, Chace DF, Meyer DL, Doronina SO, Siegall CB, Francisco JA, Senter PD, Wahl AF.
    Clin Cancer Res; 2004 Dec 01; 10(23):7842-51. PubMed ID: 15585616
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Diffuse large B-cell primary gastric lymphoma treated successfully with the CD20 monoclonal antibody (rituximab): a case with severe liver dysfunction due to liver cirrhosis and hepatocellular carcinoma.
    Nakai S, Masaki T, Shintani T, Deguchi A, Kimura Y, Himoto T, Kurokohchi K, Watanabe S, Kuriyama S.
    Oncol Rep; 2005 Jun 01; 13(6):1065-8. PubMed ID: 15870922
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
    Flavell DJ, Warnes SL, Bryson CJ, Field SA, Noss AL, Packham G, Flavell SU.
    Br J Haematol; 2006 Jul 01; 134(2):157-70. PubMed ID: 16771848
    [Abstract] [Full Text] [Related]

  • 28. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy.
    Zhou X, Hu W, Qin X.
    Oncologist; 2008 Sep 01; 13(9):954-66. PubMed ID: 18779537
    [Abstract] [Full Text] [Related]

  • 29. Empowering targeted therapy: lessons from rituximab.
    Olszewski AJ, Grossbard ML.
    Sci STKE; 2004 Jul 06; 2004(241):pe30. PubMed ID: 15252219
    [Abstract] [Full Text] [Related]

  • 30. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
    Ben Abdelwahed R, Donnou S, Ouakrim H, Crozet L, Cosette J, Jacquet A, Tourais I, Fournès B, Gillard Bocquet M, Miloudi A, Touitou V, Daussy C, Naud MC, Fridman WH, Sautès-Fridman C, Urbain R, Fisson S.
    Invest Ophthalmol Vis Sci; 2013 May 01; 54(5):3657-65. PubMed ID: 23611989
    [Abstract] [Full Text] [Related]

  • 31. CD20-negative relapse in B-cell lymphoma after treatment with Rituximab.
    Kinoshita T, Nagai H, Murate T, Saito H.
    J Clin Oncol; 1998 Dec 01; 16(12):3916. PubMed ID: 9850038
    [No Abstract] [Full Text] [Related]

  • 32. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia.
    Lauria F, Lenoci M, Annino L, Raspadori D, Marotta G, Bocchia M, Forconi F, Gentili S, La Manda M, Marconcini S, Tozzi M, Baldini L, Zinzani PL, Foà R.
    Haematologica; 2001 Oct 01; 86(10):1046-50. PubMed ID: 11602410
    [Abstract] [Full Text] [Related]

  • 33. Rituximab in indolent lymphoma: the single-agent pivotal trial.
    McLaughlin P, Hagemeister FB, Grillo-López AJ.
    Semin Oncol; 1999 Oct 01; 26(5 Suppl 14):79-87. PubMed ID: 10561022
    [Abstract] [Full Text] [Related]

  • 34. Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets.
    Maloney DG.
    Semin Oncol; 2005 Feb 01; 32(1 Suppl 1):S19-26. PubMed ID: 15786022
    [Abstract] [Full Text] [Related]

  • 35. Persistent CD20-negative primary cutaneous marginal zone lymphoma after treatment with intralesional rituximab therapy.
    Lozzi GP, Coletti G, Peris K.
    J Am Acad Dermatol; 2008 Nov 01; 59(5 Suppl):S110-2. PubMed ID: 19119114
    [No Abstract] [Full Text] [Related]

  • 36. Cutaneous B-cell lymphoma treated with rituximab infusions.
    Schneider LA.
    Acta Derm Venereol; 2006 Nov 01; 86(6):550-1. PubMed ID: 17106608
    [No Abstract] [Full Text] [Related]

  • 37. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr 01; 25(4):486-9. PubMed ID: 16613686
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases.
    Fierro MT, Savoia P, Quaglino P, Novelli M, Barberis M, Bernengo MG.
    J Am Acad Dermatol; 2003 Aug 01; 49(2):281-7. PubMed ID: 12894078
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.